Esperion Therapeutics, Inc.
ESPRNASDAQHealthcare● Active
$3.15
+$0.02(+0.48%)
Market Cap$653872921
P/E Ratio—
52W High$4.18
52W Low$0.95
Esperion Therapeutics, Inc.（ESPR）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ESPR · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.40B | $0.33B | $0.12B | $0.08B | $0.08B |
| Cost of Revenue | $0.13B | $0.07B | $0.04B | $0.03B | $0.01B |
| Gross Profit | $0.27B | $0.26B | $0.07B | $0.05B | $0.06B |
| Gross Margin %(computed) | 67.95% | 79.36% | 62.81% | 64.27% | 81.88% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.05B | $0.09B | $0.12B | $0.11B |
| G&A Expenses | $0.00B | $0.14B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.21B | $0.21B | $0.23B | $0.23B | $0.29B |
| Operating Income | $0.06B | $0.05B | ($0.16B) | ($0.18B) | ($0.23B) |
| Operating Margin %(computed) | 14.95% | 16.37% | -133.72% | -237.83% | -289.02% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.08B | $0.06B | $0.06B | $0.06B | $0.05B |
| Income Before Tax | ($0.02B) | ($0.05B) | ($0.21B) | ($0.23B) | ($0.27B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.05B) | ($0.21B) | ($0.23B) | ($0.27B) |
| Net Margin %(computed) | -5.63% | -15.57% | -179.87% | -309.58% | -343.04% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.11 | $-0.28 | $-2.03 | $-4.33 | $-11.03 |
| Wtd Avg Shares | 0.21B | 0.19B | 0.10B | 0.07B | 0.03B |
| EBITDA | $0.06B | $0.01B | ($0.15B) | ($0.18B) | ($0.22B) |
| EBITDA Margin %(computed) | 14.95% | 2.28% | -129.03% | -233.65% | -283.18% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Esperion Therapeutics, Inc.
关于Esperion Therapeutics, Inc.（ESPR）损益表
Esperion Therapeutics, Inc.（ESPR）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，ESPR实现营收$0.40B，毛利润$0.27B（毛利率67.95%），净利润($0.02B)（净利率-5.63%）。
常见问题
ESPR · 4 问Esperion Therapeutics, Inc.（ESPR）2025财年营收为$0.40B，同比up21.3%。
ESPR revenueESPR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08